menu
    • menu
    [{"orgOrder":0,"company":"BIOSYENT PHARMA INC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Polydextrose Iron Complex","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"BIOSYENT PHARMA INC","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BIOSYENT PHARMA INC \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BIOSYENT PHARMA INC \/ Not Applicable"},{"orgOrder":0,"company":"BIOSYENT PHARMA INC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Inositol","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"BIOSYENT PHARMA INC","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BIOSYENT PHARMA INC \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BIOSYENT PHARMA INC \/ Not Applicable"},{"orgOrder":0,"company":"BIOSYENT PHARMA INC","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Sodium Hyaluronate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"BIOSYENT PHARMA INC","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Suppository","sponsorNew":"BIOSYENT PHARMA INC \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"BIOSYENT PHARMA INC \/ Undisclosed"},{"orgOrder":0,"company":"BIOSYENT PHARMA INC","sponsor":"BIOSYENT PHARMA INC","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"BIOSYENT PHARMA INC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"BIOSYENT PHARMA INC \/ BIOSYENT PHARMA INC","highestDevelopmentStatusID":"1","companyTruncated":"BIOSYENT PHARMA INC \/ BIOSYENT PHARMA INC"},{"orgOrder":0,"company":"BIOSYENT PHARMA INC","sponsor":"Mithra Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Tibolone","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BIOSYENT PHARMA INC","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BIOSYENT PHARMA INC \/ BioSyent Pharma Inc","highestDevelopmentStatusID":"14","companyTruncated":"BIOSYENT PHARMA INC \/ BioSyent Pharma Inc"}]

    Find Clinical Drug Pipeline Developments & Deals by BIOSYENT PHARMA INC

    Menu

    BIOSYENT PHARMA INC

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            BIOSYENT PHARMA INC

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed

                            BIOSYENT PHARMA INC

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tibolone

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved

                            Recipient : Mithra Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            BioSyent Announces Agreement to Purchase Tibelia® (tibolone) Assets

                            Details : BioSyent has acquired intellectual property, global rights, certain licensing, distribution and supply agreements related to Tibelia (tibolone), a prescription hormone replacement therapy.

                            Brand Name : Tibelia

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 20, 2024

                            Lead Product(s) : Tibolone

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved

                            Recipient : Mithra Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            BIOSYENT PHARMA INC

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed

                            BIOSYENT PHARMA INC

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Endocrinology

                            Study Phase : Undisclosed

                            Recipient : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            BioSyent In-Licenses Endocrinology Product for Canada

                            Details : Under the licensing agreement, BioSyent aims to market, sell & distribute a new endocrinology product in Canada. BioSyent and its European partner will seek Health Canada approval by the end of 2024.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            June 12, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Undisclosed

                            Recipient : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            BIOSYENT PHARMA INC

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed

                            BIOSYENT PHARMA INC

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Hyaluronate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            BioSyent Announces Extension of RepaGyn® and Proktis-M® Agreement

                            Details : Under the agreement, BioSyent extended its agreement with its European partner for RepaGyn (sodium hyaluronate) and Proktis-M, extending its exclusive Canadian rights to these products until 2032.

                            Brand Name : Repagyn

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 15, 2024

                            Lead Product(s) : Sodium Hyaluronate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            BIOSYENT PHARMA INC

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed

                            BIOSYENT PHARMA INC

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Inositol,Folic Acid

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BioSyent Launches Inofolic® for Women with Polycystic Ovary Syndrome (PCOS)

                            Details : Inofolic is a natural health product, combining myo-inositol and folic acid in a unique soft-gel capsule for women living with PCOS. Inofolic® helped 70% of women with PCOSii to regulate their menstrual cycles throughout the 16-week study period.

                            Brand Name : Inofolic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 08, 2023

                            Lead Product(s) : Inositol,Folic Acid

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            BIOSYENT PHARMA INC

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed

                            BIOSYENT PHARMA INC

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Polydextrose Iron Complex

                            Therapeutic Area : Hematology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BioSyent Announces Launch of New FeraMAX Pd Maintenance 45

                            Details : FeraMAX (polydextrose iron complex) Maintenance 45 is designed to prevent iron deficiency, maintain healthy iron levels and to address a gap of iron health in women’s health and the management of iron health across various life stages.

                            Brand Name : FeraMAX

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 07, 2023

                            Lead Product(s) : Polydextrose Iron Complex

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth